Analyst Reco. Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Real-time Estimate Cboe BZX Other stock markets 10:10:26 2024-05-24 am EDT			5-day change	1st Jan Change
0.633 ^USD	-0.60%		-10.29%	-31.77%

May. 07	Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 06	Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Price Target on Gossamer Bio to $8 From $9, Maintains Buy Rating	Mar. 06	MT
HC Wainwright Adjusts Price Target on Gossamer Bio to $10 From $5, Keeps Buy Rating	Jan. 08	MT
Wedbush Lifts Gossamer Bio's PT to $6 From $5, Increases Multiple for Seralutinib for Pulmonary Arterial Hypertension in US, EU; Keeps Outperform Rating	Nov. 10	MT
UBS Downgrades Gossamer Bio to Neutral From Buy, Adjusts Price Target to $1.25 From $8	23-07-27	MT
Wedbush Trims Gossamer Bio's Price Target to $5 From $7, Keeps Outperform Rating	23-07-26	MT
Barclays Adjusts Price Target on Gossamer Bio $1.50 From $2, Keeps Equalweight Rating	23-03-21	MT
Raymond James Downgrades Gossamer Bio to Market Perform From Outperform	23-03-07	MT
Guggenheim Initiates Gossamer Bio at Neutral	23-03-01	MT
HC Wainwright Adjusts Gossamer Bio's Price Target to $5 From $25, Keeps Buy Rating	22-12-08	MT
Cantor Fitzgerald Lowers Price Target on Gossamer Bio to $10 From $21, Maintains Overweight Rating	22-12-07	MT
Goldman Sachs Lowers Price Target on Gossamer Bio to $10 From $22, Maintains Buy Rating	22-12-07	MT
UBS Cuts Price Target on Gossamer Bio to $8 From $19, Maintains Buy Rating	22-12-07	MT
JPMorgan Downgrades Gossamer Bio to Underweight From Neutral	22-12-07	MT
SVB Securities Adjusts Gossamer Bio's Price Target to $10 From $15, Keeps Outperform Rating	22-12-07	MT
Raymond James Adjusts Gossamer Bio's Price Target to $5 From $15, Keeps Outperform Rating	22-12-07	MT
Barclays Downgrades Gossamer Bio to Equal Weight From Overweight, Adjusts Price Target to $2 From $18	22-12-07	MT
Wedbush Cuts Gossamer Bio's PT to $7 From $19 After Results From Phase 2 Study of Seralutinib Fell Short of Expectations, Keeps Outperform Rating	22-12-07	MT
SMBC Nikko Downgrades Gossamer Bio to Neutral From Outperform, Price Target is $3	22-12-07	MT
Fed Rate Hike Fears Send US Equity Futures Struggling for Direction	22-12-06	MT
Raymond James Trims Price Target on Gossamer Bio to $15 From $18, Maintains Outperform Rating	22-11-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Analyst Reco.

Filters